Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05432648

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support.

The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.

Recruiting

Interested in participating?

Request Info

Key information

Age range

4 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Location contact

Christina Bales, MD

PRINCIPAL_INVESTIGATOR

Lindsey Albenberg, DO

CONTACT

[email protected]

267-426-0139

Lindsey Albenberg, DO

PRINCIPAL_INVESTIGATOR

Natalie Riebe, BA

CONTACT

[email protected]

2155190747

Wenjing Zong, MD

SUB_INVESTIGATOR

About this study

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The goal of SBS treatment is to achieve enteral autonomy using strategies that optimize intestinal absorption while minimizing unpleasant gastrointestinal (GI) side effects. One strategy that has emerged is the addition of soluble fiber to enteral formula, and this strategy has gained popularity in clinical practice as fiber-rich formulas comprised of blenderized whole foods have become commercially available. However, the investigators' preliminary observations suggest that patients with SBS have variable tolerance and growth outcomes on these blenderized feeds. To date, there are no clinical studies documenting the effects of dietary fiber in SBS patients and guidance in enteral nutrition advancement is lacking in this medically complex population. The current study aims to explore the tolerance of controlled fiber addition to enteral formula based on assessment of GI symptoms, and corresponding changes in microbiome composition, and metabolomics in pediatric patients with SBS versus non-SBS controls. The investigators will use a practical approach with fiber introduction and slowly advance to goal fiber intake to understand the factors leading to continuation. Stool, urine, and plasma samples collected pre- and post- intervention will help identify biomarkers that would predict successful fiber tolerance and optimize selection of patients for fiber introduction. While there is no intent to treat, mitigate, prevent, diagnose or cure the symptoms of SBS, the study may help shed light on the underlying mechanism for intolerance to dietary fiber.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Actively follows at the Children's Hospital of Philadelphia (CHOP) outpatient clinics
  • SBS arm specific: History of SBS diagnosis. History of short bowel syndrome based on surgical/imaging records. Small bowel is in continuity with some portion of colon
  • Control arm specific: No history of intestinal pathologies
  • No or negligible amount (few bites of fiber-containing foods okay) of fiber in tube feeds or by mouth at baseline
  • Less than 20% calories from oral food not containing fiber while the other 80% may be by enteral and/or parenteral feedings
  • At least 20% calories from fiber-free formula taken orally or via tube
  • Antibiotic use is allowed, however, should be on a stable regimen of antibiotics starting from 2 weeks prior to intervention until end of study or end of week 3 whichever is sooner. Instances of antibiotic use for brief courses (7-10 days) as long as sample collection is scheduled to be at least a week from the end date of antibiotics.
  • Previous history of fiber introduction failure is acceptable as long as clinically stable at the time of recruitment
  • Fiber supplementation is appropriate per primary physician
  • If subject is unable to provide full set of samples, they will still be enrolled

Exclusion criteria

  • SBS Arm specific: No diagnosis of SBS.
  • Control Arm specific: has baseline intestinal diseases
  • Small bowel and colon not in continuity (Ex: presence of ileostomy or jejunostomy)
  • >5% changes in percentage of calories from oral nutrition (PO), enteral nutrition (EN) and/or parenteral nutrition (PN) during the intervention
  • Addition/discontinuation/significant alteration to antibiotics regimen during study period
  • Primary physician does not think fiber supplementation is appropriate clinically

Treatment and study plan

Green bean puree

Dietary Supplement

Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.

Primary outcomes

  1. Symptoms

    Time frame: 3 weeks-6 months

    To assess the rate of continuation and symptoms/signs leading to discontinuation of fiber addition in SBS vs controls

Secondary outcomes

  1. Microbiome/Metabolome Changes

    Time frame: 3 weeks-6 months

    To correlate changes in clinical status on fiber to microbiome/metabolome changes in SBS vs controls

Study contacts

Contact information is provided by the study sponsor or research team.

Lindsey Albenberg, DO

CONTACT

[email protected]

2674260139

Sponsors and collaborators

Lead sponsor

Children's Hospital of Philadelphia

Other

Collaborators

  • University of Pennsylvania

Registry information

Official study title

Clinical Tolerance and Microbiome Changes Following Fiber Food Introduction in Short Bowel Syndrome

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jun 27, 2022
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.